'); //--> Back to Boston.com homepage Arts | Entertainment Boston Globe Online Cars.com BostonWorks Real Estate Boston.com Sports digitalMass Travel
Home
Help

Top Ten
1. Charles River Labs
2. TJX
3. Perini
4. Investors Fin. Svcs.
5. Gillette
6. Staples
7. OneSource
8. Reebok
9. Bright Horizons
10. State Street
2002 Globe 100

Year's Best
Company of year
Highest market value
Highest sales
Comeback of the year
Biggest stock gain
Fastest growth

Features
Overall performance
Bulls and Bears
  Bulls
  1. Clean Harbors
  2. Hologic
  3. NMT Medical
  4. DeWolfe
  5. Indevus Pharm.
  Bears
  1. Sonus Networks
  2. Art Tech. Group
  3. Praecis Pharm.
  4. American Tower
  5. Dusa Pharmaceutical
Banking
Market value
Sales
Biotech
Medical devices
Growth
  1. Cytyc
  2. Polymedica Corp.
  3. Perini
  4. Tweeter
  5. Boston Private Fin.
Telecom
Employment
Technology
IPOs
Company profiles
Globe 100 notes

Get the chart
The 2002 Globe 100
All the charts


Sections Boston Globe Online: Page One Nation | World Metro | Region Business Sports Living | Arts Editorials


Search the Globe:

Today
Yesterday

The Boston Globe OnlineBoston.com The Best in Massachusetts Business
BULLS
3.  N M T   M E D I C A L   I N C .

From bleak year to bullish one

    Globe 100
Bulls:
  1. Clean Harbors
  2. Hologic
  3. NMT Medical
  4. DeWolfe
  5. Indevus Pharmaceuticals

Bears:
  1. Sonus Networks
  2. Art Technology Group
  3. Praecis Pharmaceutical
  4. American Tower
  5. Dusa Pharmaceutical

Get the chart
   The Bulls
   The Bears
   All the charts

The Boston company had been struggling financially for more than three years. It was on the verge of running out of cash, and its stock was trading at less than a dollar at the outset of 2001.

A new chief executive and chief financial officer had been brought in to salvage the medical device company. They sold off a product line, raising $27 million. They focused the business around NMT's newest and potentially most profitable technology.

And in the process they turned what began as a bleak year on the financial markets into a bullish one. The company's stock climbed steadily throughout the one-year period, closing at $8 a share as of March 31.

"This is a company that most people had written off," said John E. Ahern, chief executive and president. "It was going to go out of business.

"But we've turned it around and set it up to be a very high-growth medical technology company in the future."

Ahern and chief financial officer Richard E. Davis said they are investing heavily in CardioSEAL, a new minimally invasive surgical device used to seal an opening in the wall of the heart in patients who have suffered from multiple strokes -- a market opportunity they believe could one day reach $2 billion.

In patients with the heart defect, they said, blood clots can form and move through the opening, leading to additional strokes. By sealing the opening, NMT hopes to reduce that risk. The technology has limited regulatory approval, and the company plans to apply for broader approval this year.

"We had a good 2001," Ahern said, "and we expect an even better 2002."

NAOMI AOKI


© Copyright 2002 Boston Globe Electronic Publishing Inc.
| Advertise | Contact us | Privacy policy |





Sponsors of the Globe 100 breakfast